BioSpace News Archive

Biotech Bay

Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics

Synthekine Inc. today announced the closing of a $100 million Series C financing led by The Column Group, with participation from both new and existing investors.

January 6, 2023
·
3 min read
Biotech Beach

Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Novan, Inc. (Nasdaq: NOVN) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for berdazimer gel, 10.3% (SB206) for the topical treatment of molluscum contagiosum (molluscum).

January 6, 2023
·
8 min read
Drug Development

Celularity’s Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohn’s Disease

Celularity Inc. announced today that its re-analysis of long term follow-up data from three legacy Phase 1, Phase 1b/2a and Phase 1b studies of its legacy placental-derived mesenchymal-like adherent stromal cell (MLASC) therapy in moderate-to-severe Crohn’s disease patients showed clinically meaningful and durable benefit for up to two years in the limited number of patients studied and warrants further investigation.

January 6, 2023
·
7 min read
Biotech Beach

Neuralace Medical Announces Upcoming Abstract Presentation at the 26th Annual North American Neuromodulation Society meeting (NANS) showcasing its FDA-cleared, Non-Invasive Axon Therapy® for Chronic Pain

Neuralace Medical, Inc. is announcing the upcoming presentation by the VA Augusta of its pilot study focused on assessing the impact of Axon Magnetic Peripheral Nerve Stimulation (mPNS).

January 6, 2023
·
2 min read
Business

Elevation Oncology Announces Pipeline Prioritization, Realignment of Resources to Advance EO-3021 and CEO Transition

Elevation Oncology, Inc. today announced plans to prioritize key research and development efforts to advance EO-3021, its potential best-in-class antibody-drug conjugate (ADC) designed to target Claudin18.2, and other pipeline programs including those through its existing partnership with Caris Life Sciences.

January 6, 2023
·
8 min read
Business

VivaVision and Everads Collaborate to Develop Durable and Effective Therapies for Retinal Diseases

VivaVision and Everads Therapy announced today that they are partnering to develop safer, more effective, and more durable treatments for retinal diseases.

January 6, 2023
·
4 min read
Drug Development

Compass Therapeutics Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer

Compass Therapeutics, Inc. today announced that the first patient has been dosed in the Phase 2 U.S. study of CTX-009 in patients with metastatic colorectal cancer who are being treated in the third- and fourth-line setting.

January 6, 2023
·
4 min read
Business

Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones

Longeveron Inc. today provided a corporate update highlighting the Company’s strategic priorities and anticipated milestones for 2023.

January 6, 2023
·
3 min read
Deals

Montrose Environmental Group Acquires Frontier Analytical Laboratories

Montrose Environmental Group, Inc. (“Montrose” or “the Company”) (NYSE: MEG) today announced the acquisition of Frontier Analytical Laboratories.

January 6, 2023
·
4 min read
FSD Pharma to Attend 41st Annual J.P. Morgan Healthcare Conference 2023

FSD Pharma Inc. announced today that senior executive management is attending the 41st Annual J.P. Morgan Healthcare Conference being held January 9-12, 2023, in San Francisco, California.

January 6, 2023
·
4 min read